Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 24Breast 5Thoracic 1Other neoplasm 1Head & Neck 1

Conditions

Breast Neoplasms 4Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 214Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × radium Ra 223 dichloride × Breast × Clear all
NCT04090398 2026-05-13

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

National Cancer Institute (NCI)

Phase 2 Active not recruiting
70 enrolled
BreastOther neoplasm

Anatomic Stage IV Breast Cancer AJCC v8

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Bayer

Phase 2 Completed
283 enrolled 22 charts
Breast

Breast Neoplasms

NCT02366130 2021-10-07

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
45 enrolled 7 charts
Breast

Breast Neoplasms

NCT02258464 2020-08-10

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Bayer

Phase 2 Terminated
99 enrolled 18 charts
Breast

Breast Neoplasms

NCT01070485 2014-06-25

BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease

Bayer

Phase 2 Completed
23 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡